Insights into mRNA expression in ADC targets in metastatic breast cancer

Kristien Borremans, PhD, KU Leuven, Louvain, Belgium, discusses findings from the UPTIDER trial (NCT04531696), which analyzed the mRNA expression of 72 antibody-drug conjugate (ADC) targets in metastatic and normal tissues from patients with metastatic breast cancer (mBC). High expression of FN1, MUC1, and HER3 was noted in metastatic samples, with HER2 and TROP2 showing moderate expression. The analysis highlights inter- and intra-patient heterogeneity, organ-specific expression, and correlations among targets, providing insights into potential ADC optimization for therapeutic precision. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.